Thyroid Cancer Diagnosis and Treatment
DOI:
https://doi.org/10.56981/Keywords:
thyroid gland neoplasia, tyrosine- kinase inhibitors, radioactive- iodine, fine-needle aspiretion biopsy.Abstract
Background: The common tumor of the endocrine glands is thyroid cancer. According to the American Cancer Society, in 2023, there will be 43,720 new cases of thyroid cancer in the country, and there will be 2120 mortality due to it. Is the 13th most common cancer overall and its prevalence continue to increase. Is a malignant tumor arising from the cells of thyroid parenchyma. Clinically it is variable, from, slowly progressing indolent tumors to more aggressive tumors with high mortality rates Thyroid cancer exists in various forms, including papillary, follicular, medullary, and anaplastic. Papillary thyroid cancer is the commonest one. If thyroid cancer identified earlier so it can be treated effectively. Surgery, radioactive iodine therapy, and molecularly targeted medicines using tyrosine kinase inhibitors are all a component of the therapy. As a result, the guidelines for the management of thyroid cancer and nodules are presented in this review, with an emphasis on diagnosis, treatment, and follow-up.
References
1. Wells SA. Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid 2015; 25: 567–610. [PMC free article] [PubMed] [Google Scholar]
2. Udayanga V, Jayarajah U, Colonne SD, et al. Quality of the patient-oriented information on thyroid cancer in the internet. Health Policy and Technology 2020; 9: 302–307. Available from: https://www.sciencedirect.com/science/article/abs/pii/S2211883720300344 [Google Scholar]
3. National Cancer Institute. A snapshot of thyroid cancer. November 5, 2014.www.cancer.gov/researchandfunding/snapshots/thyroid. Accessed January 12, 2015.
4. 4.vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614-617. doi:10.1056/NEJMp1604412PubMedGoogle ScholarCrossref
5. Liu Y, Su L, Xiao H. Review of factors related to the thyroid cancer epidemic. Int J Endocrinol. 2017;2017:5308635. doi:10.1155/2017/5308635PubMedGoogle Scholar
6. Knox MA. Thyroid nodules. Am Fam Physician. 2013; 88: 193–196. [PubMed] [Google Scholar]
7. Cooper DS, Doherty GM, Haugen BR, et al. for the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009; 19: 1167–1214. Errata in: Thyroid. 2010;20:674–675; Thyroid. 2010;20:942. [PubMed] [Google Scholar]
8. Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician. 2003; 67: 559–566. [PubMed] [Google Scholar]
9. National Cancer Institute. SEER stat fact sheets: thyroid cancer. http://seer.cancer.gov/statfacts/html/thyro.html. Accessed January 12, 2015.
10. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015 Feb;8(1):30-40. PMID: 25964831; PMCID: PMC4415174.
11. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282–289. [PubMed] [Google Scholar]
12. Mittendorf EA, Tamarkin SW, McHenry CR. The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid disease. Surgery. 2002;132:648–653. [PubMed] [Google Scholar]
13. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005; 237:794–800. [PubMed] [Google Scholar]
14. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, Duick DS, Guglielmi R, Hamilton CR, Jr, Zeiger MA, Zini M AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006; 12:63–102. [PubMed] [Google Scholar]
15. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214.[PubMed] [Google Scholar]
16. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941–1946. [PubMed] [Google Scholar]
17. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES, Mandel SJ. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med. 2000; 133:696–700. [PubMed] [Google Scholar]
18. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178:687–691.[PubMed] [Google Scholar]
19. Kim KE, Kim EK, Yoon JH, Han KH, Moon HJ, Kwak JY. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2013;37:385–391. [PubMed] [Google Scholar]
20. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253:854–860. [PubMed] [Google Scholar]
21. Kwak JY, Jung I, Baek JH, Baek SM, Choi N, Choi YJ, Jung SL, Kim EK, Kim JA, Kim JH, Kim KS, Lee JH, Moon HJ, Moon WJ, Park JS, Ryu JH, Shin JH, Son EJ, Sung JY, Na DG Korean Society of Thyroid Radiology (KSThR); Korean Society of Radiology. Image reporting and characterization system for ultrasound features of thyroid nodules: multicentric Korean retrospective study. Korean J Radiol. 2013; 14:110–117. [PMC free article] [PubMed] [Google Scholar]
22. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, Jung HK, Choi JS, Kim BM, Kim EK. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011; 260:892–899. [PubMed] [Google Scholar]
23. Kwak JY. Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab (Seoul). 2013 Jun;28(2):81-5. doi: 10.3803/EnM.2013.28.2.81. PMID: 24396658; PMCID: PMC3811719.
24. Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology. 2010; 255:260–269. [PubMed] [Google Scholar]
25. King AD, Ahuja AT, To EW, Tse GM, Metreweli C. Staging of papillary carcinoma of the thyroid: magnetic resonance imaging vs ultrasound of the neck. Clin Radiol 2000; 55: 222–6
26. Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging. 2005;5(1):157.
27. Tuttle RM. Differentiated thyroid cancer: overview of management. UpToDate. www.uptodate.com/contents/differentiated-thyroid-cancer-overview-of-management?source=search_result&search=Differentiated+thyroid+cancer%3A+overview+of+management&selectedTitle=1~150#H27. Accessed January 29, 2015.
28. Lucchini R, Monacelli M, Santoprete S, et al. Differentiated thyroid tumors: surgical indications. G Chir. 2013; 34: 153–157. [PMC free article] [PubMed] [Google Scholar]
29. Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg. 2013; 150: 249–256. [PubMed] [Google Scholar]
30. Wartofsky L, Van Nostrand D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine. 2012; 42: 506–513. [PubMed] [Google Scholar]
31. Tuttle RM. Differentiated thyroid cancer: radioiodine treatment. UpToDate. Updated July 15, 2014. www.uptodate.com/contents/differentiated-thyroid-cancer-radioiodine-treatment. Accessed January 12, 2015.
32. Smit J. Tyrosine kinase inhibitors in thyroid cancer. Endocr Abstracts. 2010;22. Abstract S5.3.
33. Exelixis. FDA approves Cometriq (cabozantinib) for treatment of progressive, metastatic medullary thyroid cancer. November 29, 2012. http://exelixis.com/investors-media/press-releases. Accessed January 21
Downloads
Published
Issue
Section
License
Copyright (c) 2023 https://creativecommons.org/licenses/by/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
